Company Description

Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia.

It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.

The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

Jyong Biotech Ltd.

Country	Taiwan
Founded	2002
IPO Date	Jun 17, 2025
Industry	Biotechnology
Sector	Healthcare
CEO	Fu-Feng Kuo

Contact Details

Address: No. 95, Xintai 5th Road, 23F-3 New Taipei City, 221 Taiwan
Phone	886 2 2732 5205
Website	jyongbio.com

Stock Details

Ticker Symbol	MENS
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001954488
CUSIP Number	G83116106
ISIN Number	KYG831161065
SIC Code	2834

Key Executives

Name	Position
Fu-Feng Kuo	Chief Executive Officer and Chairwoman of the Board
Wei Zhang	Chief Financial Officer
Dr. Fenglin Hsu Ph.D.	Chief Technology Officer and Director
Wanwen Su	Chief Science Officer

Latest SEC Filings

Date	Type	Title
Feb 6, 2026	6-K	Report of foreign issuer
Jan 9, 2026	6-K	Report of foreign issuer
Jun 30, 2025	SP 15D2	Filing
Jun 20, 2025	6-K	Report of foreign issuer
Jun 18, 2025	424B4	Prospectus
Jun 16, 2025	EFFECT	Notice of Effectiveness
Jun 16, 2025	CERT	Certification by an exchange approving securities for listing
Jun 12, 2025	8-A12B	Registration of securities
Jun 6, 2025	POS AM	Post-Effective amendments for registration statement
Apr 23, 2025	POS AM	Post-Effective amendments for registration statement

View All SEC Filings